Soares Cleverson T, Trombone Ana P F, Fachin Luciana R V, Rosa Patricia S, Ghidella Cássio C, Ramalho Rodrigo F, Pinilla Mabel G, Carvalho Alex F, Carrara Dirce N, Soares Fernando A, Belone Andrea F F
Department of Anatomic Pathology, Instituto Lauro de Souza Lima, São Paulo, Brazil.
Department of Health Science, Universidade do Sagrado Coração, São Paulo, Brazil.
Front Immunol. 2017 Aug 25;8:1035. doi: 10.3389/fimmu.2017.01035. eCollection 2017.
Leprosy, a chronic infectious disease caused by , is a major public health problem in poor and developing countries of the Americas, Africa, and Asia. MicroRNAs (miRNAs), which are small non-coding RNAs (18-24 nucleotides), play an important role in regulating cell and tissue homeostasis through translational downregulation of messenger RNAs (mRNAs). Deregulation of miRNA expression is important for the pathogenesis of various neoplastic and non-neoplastic diseases and has been the focus of many publications; however, studies on the expression of miRNAs in leprosy are rare. Herein, an extensive evaluation of differentially expressed miRNAs was performed on leprosy skin lesions using microarrays. Leprosy patients, classified according to Ridley and Jopling's classification or reactional states (R1 and R2), and healthy controls (HCs) were included. Punch biopsies were collected from the borders of leprosy lesions (10 tuberculoid, 10 borderline tuberculoid, 10 borderline borderline, 10 borderline lepromatous, 4 lepromatous, 14 R1, and 9 R2) and from 9 HCs. miRNA expression profiles were obtained using the Agilent Microarray platform with miRBase, which consists of 1,368 (hsa)-miRNA candidates. TaqMan quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) was used to validate differentially expressed miRNAs. Sixty-four differentially expressed miRNAs, including 50 upregulated and 14 downregulated (fold change ≥2.0, -value ≤ 0.05) were identified after comparing samples from patients to those of controls. Twenty differentially expressed miRNAs were identified exclusively in the reactional samples (14 type 1 and 6 type 2). Eight miRNAs were validated by RT-PCR, including seven upregulated (hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-146b-5p, hsa-miR-342-3p, hsa-miR-361-3p, hsa-miR-3653, and hsa-miR-484) and one downregulated (hsa-miR-1290). These miRNAs were differentially expressed in leprosy and several other diseases, especially those related to the immune response. Moreover, the integration of analysis of validated mi/mRNAs obtained from the same samples allowed target pairs opposite expression pattern of hsa-miRNA-142-3p and AKR1B10, hsa-miRNA-342-3p and FAM180b, and hsa-miRNA-484 and FASN. This study identified several miRNAs that might play an important role in the molecular pathogenesis of the disease. Moreover, these deregulated miRNAs and their respective signaling pathways might be useful as therapeutic markers, therapeutic targets, which could help in the development of drugs to treat leprosy.
麻风病是一种由 引起的慢性传染病,在美洲、非洲和亚洲的贫穷及发展中国家是一个主要的公共卫生问题。微小RNA(miRNA)是小的非编码RNA(18 - 24个核苷酸),通过使信使RNA(mRNA)的翻译下调,在调节细胞和组织内稳态中发挥重要作用。miRNA表达失调对各种肿瘤性和非肿瘤性疾病的发病机制很重要,并且一直是许多出版物关注的焦点;然而,关于miRNA在麻风病中表达的研究很少。在此,我们使用微阵列对麻风病皮肤病变中差异表达的miRNA进行了广泛评估。纳入了根据里德利和乔普林分类法或反应状态(R1和R2)分类的麻风病患者以及健康对照(HC)。从麻风病病变边缘(10例结核样型、10例界线结核样型、10例中间界线型、10例界线类偏瘤型、4例瘤型、14例R1和9例R2)和9例HC中采集打孔活检组织。使用包含1368个(hsa)-miRNA候选物的Agilent微阵列平台与miRBase获得miRNA表达谱。使用TaqMan定量实时逆转录聚合酶链反应(RT-PCR)验证差异表达的miRNA。在将患者样本与对照样本进行比较后,鉴定出64个差异表达的miRNA,包括50个上调和14个下调(倍数变化≥2.0,-值≤0.05)。在反应性样本(14例1型和6例2型)中专门鉴定出20个差异表达的miRNA。通过RT-PCR验证了8个miRNA,包括7个上调的(hsa-miR-142-3p、hsa-miR-142-5p、hsa-miR-146b-5p、hsa-miR-342-3p、hsa-miR-361-3p、hsa-miR-3653和hsa-miR-484)和1个下调的(hsa-miR-1290)。这些miRNA在麻风病和其他几种疾病中差异表达,尤其是那些与免疫反应相关的疾病。此外,对从同一样本获得的经过验证的mi/mRNA进行综合分析,发现hsa-miRNA-142-3p与AKR1B10、hsa-miRNA-342-3p与FAM180b以及hsa-miRNA-484与FASN存在靶标对的相反表达模式。本研究鉴定出了几种可能在该疾病分子发病机制中起重要作用的miRNA。此外,这些失调的miRNA及其各自的信号通路可能作为治疗标志物、治疗靶点有用,这有助于开发治疗麻风病的药物。